Israel's biotechnology sector is poised to attract more investment from venture capital funds over the course of the year, according to an Israel Venture Capital research paper.
According to Eyal Solomon, of the Ethosia human resources firm, biotechnology in Israel has the strength to withstand any downturns in global markets.
"If we do feel the effects [of an economic downturn], it will only be seen in two quarters' time," he said. "The venture capital funds have money in the 'pipeline,' and their investors want to see results. They can't just sit on the money."
IVC expects the biotechnology sector to attract 12 percent more investment this year. Though health care organizations around the world, private and public, are increasingly trying to cut costs, there is still ample opportunity for innovative products to make money by addressing unresolved medical problems, or to make existing procedures safer, cheaper and more effective. And venture capital funds are eager to find the next big
No comments:
Post a Comment